ClinicalTrials.gg
CompletedNCT01973205Updated Jun 11, 2015Results posted

Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine

A Phase 3 interventional study of Acetaminophen 250 mg and Aspirin 250 mg and Placebo in Acute Migraine, sponsored by Novartis. Completed at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-11.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing acetaminophen in Migraine Disorders — 1 open to participants now, 1 under way, none of them phase 3. Acetaminophen · Migraine Disorders.

Enrollment
2nd of 15
900 · median 200
Started
2013
the only one that year
Phase 3
3 of 15
none open now
Registered
5th of 15
by date
Lead sponsor
2 of 15
Novartis

Among the 15 studies testing acetaminophen in Migraine Disorders, this one is the 2nd largest by enrollment, is the only one that started in 2013, is one of 3 in phase 3, and was the 5th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

1 of the 15 studies testing acetaminophen in Migraine Disorders is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing acetaminophen in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of acetaminophen and aspirin versus placebo in the acute treatment of migraine

03

Conditions studied

  • Acute Migraine

Browse trials for

Keywords

  • Migraine
  • acetaminophen
  • aspirin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18 years and over.
  2. International Headache Society (IHS) diagnosis of migraine without aura or typical aura with migraine headache.
  3. History of experiencing at least 1, but not more than 8, acute migraine attacks monthly during the previous year.
  4. History of at least moderate migraine pain intensity, if left untreated.
  5. History of frequently or always experiencing nausea with the migraine attack.

Exclusion criteria

Exclusion criteria:

Subjects eligible for inclusion in this study must not fulfill any of the following criteria:

  1. Headache symptoms which may be due to or aggravated by:

    • Recent (within 6 months) head or neck trauma (e.g., whiplash)
    • Head or neck pain secondary to an orthopedic abnormality
    • Cluster headache
    • Specific migraine variants (e.g., basilar-type artery migraine, opthalmoplegic migraine, hemiplegic migraine, migraine aura without headache)
    • Other serious, non-migraine causes of headache (e.g., increased intracranial pressure, intracranial bleeding, meningitis, )
    • Non-serious, non-migraine causes of headache (e.g., cold, flu, hangover)
  2. History of vomiting during more than 20% of migraine attacks.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
900 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets

    Drug: Placebo

  • Experimental
    Acetaminophen 250 mg and aspirin 250 mg

    2 tablets each containing Acetaminophen 250 mg and aspirin 250 mg

    Drug: Acetaminophen 250 mg and Aspirin 250 mg

Interventions

  • DrugAcetaminophen 250 mg and Aspirin 250 mg

    Drug page: Acetaminophen

    2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg

  • DrugPlacebo

    2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets

06

What researchers measure

Primary outcomes

  1. Number of Subjects Who Are Pain Free at the 2-hour Assessment

    Number of subjects who are pain free at the 2-hour assessment

    Time frame: 2 hours

  2. Number of Subjects Who Are Nausea Free at the 2-hour Assessment

    Number of subjects who are nausea free at the 2-hour assessment

    Time frame: 2 hours

Secondary outcomes

  1. Number of Subjects Who Are Free of Photophobia at the 2-hour Assessment.

    Number of subjects who are free of photophobia at the 2-hour assessment.

    Time frame: 2 hours

  2. Number of Subjects Who Are Free of Phonophobia at the 2-hour Assessment.

    Number of subjects who are free of phonophobia at the 2-hour assessment.

    Time frame: 2 hours

07

Results

Posted Jun 11, 2015

Participant flow

Participant flow — Overall Study
MilestonePlaceboAcetaminophen 250 mg and Aspirin 250 mg
Started453447
Completed423425
Not completed3022

Outcome measures

PrimaryNumber of Subjects Who Are Pain Free at the 2-hour Assessment

Number of subjects who are pain free at the 2-hour assessment

Time frame:
2 hours
Reported as:
Number · participants
Number of Subjects Who Are Pain Free at the 2-hour Assessment
participantsPlaceboAcetaminophen 250 mg and Aspirin 250 mg
Number of Subjects Who Are Pain Free at the 2-hour Assessment6990
PrimaryNumber of Subjects Who Are Nausea Free at the 2-hour Assessment

Number of subjects who are nausea free at the 2-hour assessment

Time frame:
2 hours
Reported as:
Number · participants
Number of Subjects Who Are Nausea Free at the 2-hour Assessment
participantsPlaceboAcetaminophen 250 mg and Aspirin 250 mg
Number of Subjects Who Are Nausea Free at the 2-hour Assessment208244
SecondaryNumber of Subjects Who Are Free of Photophobia at the 2-hour Assessment.

Number of subjects who are free of photophobia at the 2-hour assessment.

Time frame:
2 hours
Reported as:
Number · participants
Number of Subjects Who Are Free of Photophobia at the 2-hour Assessment.
participantsPlaceboAcetaminophen 250 mg and Aspirin 250 mg
Number of Subjects Who Are Free of Photophobia at the 2-hour Assessment.116127
SecondaryNumber of Subjects Who Are Free of Phonophobia at the 2-hour Assessment.

Number of subjects who are free of phonophobia at the 2-hour assessment.

Time frame:
2 hours
Reported as:
Number · participants
Number of Subjects Who Are Free of Phonophobia at the 2-hour Assessment.
participantsPlaceboAcetaminophen 250 mg and Aspirin 250 mg
Number of Subjects Who Are Free of Phonophobia at the 2-hour Assessment.142164

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/415 (0%)0/415 (0%)
Acetaminophen 250 mg and Aspirin 250 mg—1/408 (0.2%)0/408 (0%)
Most frequent serious events
Most frequent serious events
EventPlaceboAcetaminophen 250 mg and Aspirin 250 mg
intraductal profilerative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4151/408

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboAcetaminophen 250 mg and Aspirin 250 mgTotal
Mean40.6 ± 12.439.7 ± 12.840.1 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAcetaminophen 250 mg and Aspirin 250 mgTotal
Female351350701
Male10297199
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAcetaminophen 250 mg and Aspirin 250 mgTotal
Hispanic or Latino484896
Not Hispanic or Latino405399804
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAcetaminophen 250 mg and Aspirin 250 mgTotal
American Indian or Alaska Native101
Asian5510
Native Hawaiian or Other Pacific Islander112
Black or African American96105201
White337318655
More than one race000
Unknown or Not Reported131831
Region of Enrollment
Region of Enrollment(participants)PlaceboAcetaminophen 250 mg and Aspirin 250 mgTotal
United States453447900
08

Study locations

19 sites
  • Birmingham, Alabama, United States
  • Anaheim, California, United States
  • San Francisco, California, United States
  • Ft Lauderdale, Florida, United States
  • Jupiter, Florida, United States
  • Oviedo, Florida, United States
  • West Palm Beach, Florida, United States
  • Evansville, Indiana, United States
  • Ann Arbor, Michigan, United States
  • Berlin, New Jersey, United States
  • Bronx, New York, United States
  • Rochester, New York, United States
  • Williamsville, New York, United States
  • Raleigh, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Mount Pleasant, South Carolina, United States
  • Salt Lake City, Utah, United States
  • Kenosha, Wisconsin, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2013
First posted
Oct 31, 2013
Start
Oct 2013
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Results first posted
Jun 11, 2015
Last update
Jun 11, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01973205
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Oct 31, 2013
Start date
Oct 2013
Primary completion
Jul 2014
Completion
Jul 2014
Results posted
Jun 11, 2015
Last update
Jun 11, 2015

Study contacts

Clinical Project Lead
study director · Novartis Consumer Health

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion